Endocrine Fellows Series: Type 1 Diabetes Care and Management

San Diego, CA US

Monday, March 2, 2015 – Tuesday, March 3, 2015
Hilton San Diego Bayfront Hotel, Indigo Ballroom D

The second annual Endocrine Fellows Series: Type 1 Diabetes Care and Management is a live CME-certified conference of pediatric and adult endocrine fellows held prior to ENDO 2015 (March 5-8, 2015) in San Diego, California. Fellows attend group discussions, clinical case presentations, and networking sessions with expert faculty over the two-day program. Sessions include sick day and hospital management, insulin pumps and CGM, psychosocial factors, transitional care, and more. This year's application period is currently closed. For details on the current and future programs, visit endocrine.org/t1dmfellows.

This activity is supported by educational grants from AstraZeneca LP, The Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; and Novo Nordisk Inc.

Target Audience

This continuing medical education activity should be of substantial interest to pediatric and adult endocrine fellows.

Learning Objectives

Upon completion of this educational activity, participants will be able to (or better able to):

  • Differentially diagnose T1D in youth and assess the familial risk of developing T1D
  • Utilize patient education and counseling to motivate patients and their caregivers and promote adherence
  • Apply current clinical information to set appropriate blood glucose targets taking into consideration a patient’s lifestyle, age and condition
  • Evaluate clinical practice guidelines on the prevention, screening and management of comorbidities
  • Explain the neurological consequences of hypoglycemia and hyperglycemia and recognize potential causes
  • Recognize special considerations in the management of diabetes in a trauma or in-patient setting
  • Discuss the important of individualized nutrition plans and goals for patients with T1D
  • Discuss the potential risks and benefits associated with emerging therapies for diabetes

Additional Information

Target Audience: 
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Diabetes and Glucose Metabolism
General Endocrinology
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 15.50 AMA PRA Category 1 Credits
  • 15.50 CME Certificate of Participation
Course opens: 
Course expires: 
Hilton San Diego Bayfront
1 Park Boulevard
Indigo Ballroom D
San Diego, CA 92101
United States

Program Directors

Irl B. Hirsch, MD; Univ of Washington Sch of Med
Linda Siminerio, PhD; Univ of Pittsburgh Diabetes Institute


Timothy Bailey, MD; Advanced Metabolic Care and Research Institute Inc.
Roy W. Beck, MD, PhD; Jaeb Ctr for Hlth Res/Univ of S Florida
Bruce A. Buckingham, MD; Stanford Univ Sch of Med
Luisa Duran, MD; John Muir Health
Clark Joseph Eckel; Denver Colorado
Jami Dinsmore Eckel; Denver, Colorado
Margaret Scarborough Eckel; Denver, Colorado
Robert H. Eckel, MD; Univ of Colorado Sch of Med
Alison Evert, MS, RD, CDE; University of Washington
Carla Greenbaum, MD, Benaroya Research Institute
Susan Guzman, PhD; Behavioral Diabetes Institute
Irl B. Hirsch, MD; Univ of Washington Sch of Med
David Maahs, MD; Barbara Davis Center for Diabetes
Janet McGill, MD; University of Washington
Michael C. Riddell, PhD; York Univ (Canada)
Linda Siminerio, PhD; University of Pittsburgh Diabetes Institute
Sandra Sobel, MD; University of Pittsburgh
Guillermo E. Umpierrez, MD, CDE; Emory Univ
Joseph Wolfsdorf, MD, BCh; Boston Children’s Hosp


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Bruce A. Buckingham, MD: Advisory Board Member, Animas, Halozyme, Novo Nordisk, Sanofi; Advisory Board Member and Investigator, Convatec, Medtronic, Tandem; Investigator, Bayer, Dexcom;
Timothy Bailey, MD: Consultant, Research Support & Speaker, Novo Nordisk; Consultant and Reseach Support, Bayer, BD, Medtronic, Sanofi; Consultant, Abbott, ACON, Alere, Animas, Bristol Myers Squibb, Cebix, Dexcom, GlaxoSmithKline, Halozyme, Insulet, Lifescan, Lilly, Mannkind, Merck, Orexigen, Tandem
Robert H. Eckel, MD: Advisory Board Member and Consultant, Amarin, Amgen, Esperion, Genentech, ISIS, Janssen, Novo Nordisk, Pfizer, Regeneron/sanof-aventis; Research Grant Support, Esperion, Janssesn, ISIS 
Irl B. Hirsch, MD: Advisory Board Member, Abbott Laboratories; Consultant, Roche Pharmaceuticals, Valeritas; Principal Investigator, Halozyme, Novo Nordisk, Sanofi
Janet McGill, MD: Advisory Board Member, Abbott Laboratories, AbbVie, AstraZeneca, Aventis Pharmaceuticals, Eli Lilly, Merck & Co., Novo Nordisk, sanofi; Consultant, Boehringer Ingelheim, Mannkind; Investigator, Dexcom, Novartis Pharmaceuticals, Pfizer Global R&D; Speaker, Janssen Pharmaceuticals
Michael C. Riddell, PhD: Ad Hoc Consultant, Medtronic Minimed; Speaker, Eli Lilly & Company, Sanofi
Guillermo E. Umpierrez, MD, CDE: Consultant, Boehringer Ingelheim, Merck & Co., Novo Nordisk; Investigator, Boehringer Ingelheim, Merck & Co.
Joseph Wolfsdorf, MD, BCh: Editor, Up To Date

The following faculty reported no relevant financial relationships: Roy W. Beck, MD, PhD; Luisa Duran, MD; Clark Joseph Eckel; Jami Dinsmore Eckel; Margaret Scarborough Eckel; Alison Evert, MS, RD, CDE; Carla Greenbaum, MD; Susan Guzman, PhD; David Maahs, MD; Linda Siminerio, PhD; Sandra Sobel, MD.

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 15.50 AMA PRA Category 1 Credits
  • 15.50 CME Certificate of Participation